Ferric Derisomaltose interactions
Full monograph for Ferric DerisomaltoseCheck it against another medicine
Medicines
32 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
| Captopril | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Carbonyl Iron + Folic Acid | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Enalapril Maleate | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Ferric Maltol | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Ferrous Fumarate + Folic acid | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron + Folic Acid + Vitamin A + Vitamin C + Zinc | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron + Folic acid + Vitamin B complex + Vitamin C | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron + Folic Acid + Vitamin B Complex + Vitamine C + Zinc Sulfate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron Polymaltose Complex | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc + Vitamin B-Complex | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc Sulfate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Iron Polymaltose Complex + Vitamin B Complex + Zinc | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Lisinopril | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Norgestrel + Ethinyl Estradiol + Ferrous Fumarate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Perindopril + Indapamide | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Perindopril Arginine | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Perindopril Arginine + Amlodipine | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Ramipril | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Ramipril + Hydrochlorothiazide | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Tea Tree Oil + Geothermal Water + Vitamin E | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
| Vitamin B12 + Elemental Iron + Folic Acid | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Vitamin C + Vitamin E | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
| Vitamin C + Vitamin E + Lutein + Copper + Zinc | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
Conditions
Conditions in which Ferric Derisomaltose needs care, as documented in this source.
Iron Overload
ModerateFerric derisomaltose should not be administered to patients with iron overload.
1 source
- "Product Information. Monoferric (ferric derisomaltose)." Pharmacosmos Therapeutics (2022):
Therapeutic duplication
Drug classes that overlap with Ferric Derisomaltose, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
iron preparations
The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'iron preparations' category.
Example product in the source data (US market): Ferrous fumarate/iron polysaccharide
iron preparations
The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'iron preparations' category.
Example product in the source data (US market): Hemocyte-f
iron preparations
The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'iron preparations' category.
Example product in the source data (US market): Vitron-c